logo
Menu
Innovation Observatory > Reports > Infectious Disease and Immunisation

Results

Drugs

January 2018

RBX-2660 for the Treatment of Recurrent Clostridium Difficile Infection – third line

RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.

Drugs

March 2017

Cefiderocol for severe gram-negative infections

Cefiderocol is a new drug to treat severe infections, which are caused by a particular group of bacteria called gram-negative bacteria, which are increasingly resistant to many antibiotics. Infections such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patient stay in hospital …

Drugs

January 2017

Meropenem/vaborbactam (Carbavance) for treatment resistant gram-negative bacterial infections – first line

Hospital acquired infections, such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patients’ stay in hospital and increase healthcare costs. These infections are frequently caused by types of bacteria that are becoming resistant to commonly prescribed antibiotics. Resistance to antibiotics is a …

Drugs

December 2016

Zanamivir (Relenza) as an intravenous formulation for the treatment of hospitalised patients with influenza

Zanamivir is a new drug to treat patients who have been admitted to hospital with influenza. It is for patients who are not responding to other antiviral medicines or who are only able to receive treatment via a drip; it is also an option for patients who are infected with influenza virus which is resistant …

Drugs

December 2016

Plazomicin for treatment of multi-drug resistant Gram-negative Enterobacteriaceae infections

Hospital acquired infections, such as pneumonia, complicated urinary tract infections and bloodstream infections, are serious infections and a huge problem for the NHS. They prolong patients’ stay in hospital and increase health costs. These infections are frequently caused by types of bacteria that are becoming increasingly resistant to commonly prescribed antibiotics. Resistance to antibiotics is …

Drugs

December 2016

MK3682B (uprifosbuvir, ruzasvir and grazoprevir) for hepatitis C infection – first line

MK3682B is a combination of three drugs in a tablet that is taken by mouth to treat patients with the hepatitis C virus. Hepatitis C is a virus that causes inflammation and damage to the liver. MK3682B stops the hepatitis C virus from reproducing correctly, stopping or reducing damage to the liver. Some studies have …

Drugs

July 2016

Relebactam in combination with imipenem and cilastatin for the treatment of drug resistant Gram-negative infections

Hospital acquired infections: including hospital acquired pneumonia, ventilator associated pneumonia, complicated urinary tract infections and complicated intra-abdominal infections are serious infections and a huge problem for the NHS. They prolong patients’ stay in hospital and increase health costs. These infections are frequently caused by Gram negative bacteria that are becoming increasingly resistant to commonly prescribed …

Drugs

May 2016

Letermovir for the prevention of cytomegalovirus infection in sero-positive patients undergoing allogeneic haematopoietic stem cell transplantation

Cytomegalovirus is a common virus and most people become infected in childhood. The virus is spread through bodily fluids, such as saliva or urine, and can easily be spread by close contact with children, such as when changing nappies. Once someone becomes infected, the cytomegalovirus will stay in their body for the rest of their …

Drugs

May 2016

Glecaprevir with pibrentasvir for chronic hepatitis C infection, genotypes 1, 2, 3, 4, 5 and 6

Hepatitis C is a virus that causes inflammation of the liver. The virus is most commonly passed on by needles contaminated with infected blood, but it is also occasionally spread through unprotected sex. Most people with hepatitis C will have it for many years and they may or may not have symptoms. If the virus …

Drugs

May 2016

Cadazolid for treatment of Clostridium difficile-associated diarrhoea

Clostridium difficile is a bacterium that infects the gut and causes diarrhoea. It usually affects people who have recently taken antibiotics and it can cause serious bowel problems if left untreated. The bacterium is easily spread by direct contact with infected people or surfaces. Cadazolid is a new antibiotic that is taken by mouth as …

Get Alerts